Poland· PL-100531317

Femoston

A dydrogesteron und estrogen product containing estradiolum, estradiolum + dydrogesteronum, registered in Poland by Delfarma Sp. z o.o.. The same ATC class is registered in 9 of our 19 countries.

ATC G03FB08

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedFemostonATCG03FB08REGISTER NO.PL-100531317PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Dydrogesteron und estrogen is registered in 9 of 19 countries.

Countries holding a registration under ATC G03FB08 (dydrogesteron und estrogen), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose

Dydrogesteron und estrogen · ATC G03FB08

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Estradiolum, Estradiolum + Dydrogesteronum
Manufacturer
Delfarma Sp. z o.o.
Country
Poland (PL)
ATC code
G03FB08
ATC class
Dydrogesteron und Estrogen
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991592783
  • gtin
    05909991592790

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for dydrogesteron und estrogen.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Dydrogesteron und estrogen · interactions on record

3 records

3 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c331b83a-f1af-4bf7-bbd1-098611ec3b93
GET /v1/drugs/c331b83a-f1af-4bf7-bbd1-098611ec3b93?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "2 mg (ceglastoczerwone), 2 mg + 10 mg (żółte)",
  "packaging": "05909991592783 ¦ Rp ¦ 165467\n28 tabl.\n05909991592790 ¦ Rp ¦ 165468\n84 tabl.",
  "substance": null,
  "common_name": "Estradiolum, Estradiolum + Dydrogesteronum",
  "pl_product_id": "100531317",
  "pozwolenie_nr": "017/26",
  "auth_procedure": "IR",
  "authorisation_validity": "2031-01-20"
}

See everything about dydrogesteron und estrogen.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.